Artificial intelligence (AI) is rapidly playing a pivotal role in transforming the biopharmaceutical landscape, including its influence on every stage from drug discovery to development and commercialization. As the USPTO shifts patent policy to keep pace with this explosive growth, licensing deals have likewise become increasingly dynamic to account for the new challenges that AI poses in the areas of data sharing, confidentiality, inventorship, patentability, IP ownership, and other areas.

In this webinar, LES USA-Canada's Life Sciences Sector will delve into this complex situation and provide an analytical framework to help companies analyze how to effectively leverage AI in several exemplary deal scenarios.